Newer Therapies in Psoriasis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34059242.
- Also identified by DOI 10.1016/j.mcna.2021.04.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Psoriasis is a systemic inflammatory condition that negatively affects the quality of life and medical health of 125 million individuals globally. Although psoriasis has historically been viewed as a skin-limited disease and managed with topical agents (eg, coal tar, corticosteroids, and vitamin D analogues), the recontextualization of psoriasis as a systemic condition involving multiple organ systems has prompted the development of numerous immunomodulating, systemic agents with more targeted mechanisms of action. This article briefly discusses the indications and nuances of new and developing therapeutic agents for psoriasis management.
Medical subject headings
- Interleukins
- Psoriasis
- Tumor Necrosis Factor-alpha